{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-084207","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.317748+00:00","generated_at":"2026-05-15T22:44:06.821271+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dyne posts FY2025 net loss $446M; z-rostudirsen BLA submission on track for Q2 2026","bullets":["Net loss $446.2M ($3.47/share) for FY2025 vs $317.4M ($3.37/share) in FY2024; R&D expense $398.3M.","Cash $1.1B at Dec 31, 2025; expected runway into Q1 2028.","Z-rostudirsen in DMD met primary endpoint: dystrophin 5.46% of normal (p<0.0001); BLA submission planned Q2 2026.","Z-basivarsen in DM1: enrollment completion of registrational cohort expected Q2 2026; topline data Q1 2027.","Advancing four DMD exon-skipping candidates (exons 53, 45, 44, 55) into IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-084207","json":"https://secwatch.observer/filing/0001193125-26-084207.json","markdown":"https://secwatch.observer/filing/0001193125-26-084207.md","text":"https://secwatch.observer/filing/0001193125-26-084207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526084207/0001193125-26-084207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526084207/dyn-20260302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:44:06.821271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}